ArticleEClinicalMedicine2023

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.

Elena Zamagni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.